CD8A and neoplasm: As shown in Fig. 6, the combined use of DMF and anti-PD-L1 antibody significantly increased the number of tumor-infiltrating CD8+ T cells and the levels of granzyme B, thereby enhancing the efficacy of immunotherapy in mice.